FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001150235> ?p ?o ?g. }

• W2001150235 endingPage "638.e10" @default.
• W2001150235 startingPage "638" @default.
• W2001150235 abstract "Purpose To evaluate the efficacy and safety of photodynamic therapy (PDT) with verteporfin combined with intravitreal triamcinolone (IVTA) in occult choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Design Single center, nonrandomized interventional case series. Methods A prospective, noncomparative, interventional case series of 41 eyes of 41 patients with a two-year follow-up period. Verteporfin PDT was performed using the recommended standard procedure for approved forms of AMD. A solution containing 25 mg of crystalline triamcinolone acetonide was injected intravitreally 16 hours post PDT. The procedure was repeated after three months in case of persistent CNV leakage. Results The mean number of treatments needed was 1.8. Thirty-four eyes (82.9%) required one retreatment at three months. No additional retreatments were necessary. Visual acuity improved gradually in most of the patients with mean values of 20/133 and 20/115 at baseline and three months; 20/101 and 20/84 at six and twelve months; and 20/83 and 20/81 at eighteen and twenty-four months. Eleven of 41 treated study eyes (26.8%) underwent cataract surgery between six and fifteen months after the first treatment. Nine patients required local or systemic glaucoma therapy because of a transient steroid induced intraocular pressure increase. Conclusions Verteporfin PDT combined with intravitreal triamcinolone may improve the outcome of standard verteporfin PDT in the treatment of occult CNV secondary to AMD. An improvement in visual acuity was observed in most of the treated patients and was maintained during a two-year follow-up period. Retreatment numbers were lower than expected from monotherapy trials. To evaluate the efficacy and safety of photodynamic therapy (PDT) with verteporfin combined with intravitreal triamcinolone (IVTA) in occult choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Single center, nonrandomized interventional case series. A prospective, noncomparative, interventional case series of 41 eyes of 41 patients with a two-year follow-up period. Verteporfin PDT was performed using the recommended standard procedure for approved forms of AMD. A solution containing 25 mg of crystalline triamcinolone acetonide was injected intravitreally 16 hours post PDT. The procedure was repeated after three months in case of persistent CNV leakage. The mean number of treatments needed was 1.8. Thirty-four eyes (82.9%) required one retreatment at three months. No additional retreatments were necessary. Visual acuity improved gradually in most of the patients with mean values of 20/133 and 20/115 at baseline and three months; 20/101 and 20/84 at six and twelve months; and 20/83 and 20/81 at eighteen and twenty-four months. Eleven of 41 treated study eyes (26.8%) underwent cataract surgery between six and fifteen months after the first treatment. Nine patients required local or systemic glaucoma therapy because of a transient steroid induced intraocular pressure increase. Verteporfin PDT combined with intravitreal triamcinolone may improve the outcome of standard verteporfin PDT in the treatment of occult CNV secondary to AMD. An improvement in visual acuity was observed in most of the treated patients and was maintained during a two-year follow-up period. Retreatment numbers were lower than expected from monotherapy trials." @default.
• W2001150235 created "2016-06-24" @default.
• W2001150235 creator A5053563726 @default.
• W2001150235 creator A5084748737 @default.
• W2001150235 date "2006-04-01" @default.
• W2001150235 modified "2023-10-16" @default.
• W2001150235 title "Verteporfin and Intravitreal Triamcinolone Acetonide Combination Therapy for Occult Choroidal Neovascularization in Age-Related Macular Degeneration" @default.
• W2001150235 cites W134105562 @default.
• W2001150235 cites W1526593603 @default.
• W2001150235 cites W1573851418 @default.
• W2001150235 cites W1601975653 @default.
• W2001150235 cites W1964499056 @default.
• W2001150235 cites W1978199957 @default.
• W2001150235 cites W1981362657 @default.
• W2001150235 cites W1996949783 @default.
• W2001150235 cites W1997013893 @default.
• W2001150235 cites W2001263805 @default.
• W2001150235 cites W2003167604 @default.
• W2001150235 cites W2003822242 @default.
• W2001150235 cites W2039243428 @default.
• W2001150235 cites W2045317893 @default.
• W2001150235 cites W2083092631 @default.
• W2001150235 cites W2094310573 @default.
• W2001150235 cites W2094868073 @default.
• W2001150235 cites W2099490431 @default.
• W2001150235 cites W2103863709 @default.
• W2001150235 cites W2108762814 @default.
• W2001150235 cites W2125483843 @default.
• W2001150235 cites W2129949645 @default.
• W2001150235 cites W2135333970 @default.
• W2001150235 cites W2149579095 @default.
• W2001150235 cites W2154462339 @default.
• W2001150235 cites W2165265638 @default.
• W2001150235 cites W2166108068 @default.
• W2001150235 cites W2168858270 @default.
• W2001150235 cites W2170353976 @default.
• W2001150235 cites W3202352366 @default.
• W2001150235 cites W945208301 @default.
• W2001150235 doi "https://doi.org/10.1016/j.ajo.2005.11.058" @default.
• W2001150235 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16564797" @default.
• W2001150235 hasPublicationYear "2006" @default.
• W2001150235 type Work @default.
• W2001150235 sameAs 2001150235 @default.
• W2001150235 citedByCount "85" @default.
• W2001150235 countsByYear W20011502352012 @default.
• W2001150235 countsByYear W20011502352014 @default.
• W2001150235 countsByYear W20011502352015 @default.
• W2001150235 countsByYear W20011502352016 @default.
• W2001150235 crossrefType "journal-article" @default.
• W2001150235 hasAuthorship W2001150235A5053563726 @default.
• W2001150235 hasAuthorship W2001150235A5084748737 @default.
• W2001150235 hasConcept C118487528 @default.
• W2001150235 hasConcept C141071460 @default.
• W2001150235 hasConcept C2776251621 @default.
• W2001150235 hasConcept C2776403814 @default.
• W2001150235 hasConcept C2778257484 @default.
• W2001150235 hasConcept C2778903070 @default.
• W2001150235 hasConcept C2781092963 @default.
• W2001150235 hasConcept C2781148688 @default.
• W2001150235 hasConcept C2781359195 @default.
• W2001150235 hasConcept C71924100 @default.
• W2001150235 hasConceptScore W2001150235C118487528 @default.
• W2001150235 hasConceptScore W2001150235C141071460 @default.
• W2001150235 hasConceptScore W2001150235C2776251621 @default.
• W2001150235 hasConceptScore W2001150235C2776403814 @default.
• W2001150235 hasConceptScore W2001150235C2778257484 @default.
• W2001150235 hasConceptScore W2001150235C2778903070 @default.
• W2001150235 hasConceptScore W2001150235C2781092963 @default.
• W2001150235 hasConceptScore W2001150235C2781148688 @default.
• W2001150235 hasConceptScore W2001150235C2781359195 @default.
• W2001150235 hasConceptScore W2001150235C71924100 @default.
• W2001150235 hasIssue "4" @default.
• W2001150235 hasLocation W20011502351 @default.
• W2001150235 hasLocation W20011502352 @default.
• W2001150235 hasOpenAccess W2001150235 @default.
• W2001150235 hasPrimaryLocation W20011502351 @default.
• W2001150235 hasRelatedWork W1615644543 @default.
• W2001150235 hasRelatedWork W2085712747 @default.
• W2001150235 hasRelatedWork W2128574114 @default.
• W2001150235 hasRelatedWork W2275898654 @default.
• W2001150235 hasRelatedWork W2329828213 @default.
• W2001150235 hasRelatedWork W2917472240 @default.
• W2001150235 hasRelatedWork W2991715136 @default.
• W2001150235 hasRelatedWork W3133592287 @default.
• W2001150235 hasRelatedWork W4236537787 @default.
• W2001150235 hasRelatedWork W4241671912 @default.
• W2001150235 hasVolume "141" @default.
• W2001150235 isParatext "false" @default.
• W2001150235 isRetracted "false" @default.
• W2001150235 magId "2001150235" @default.
• W2001150235 workType "article" @default.